X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

The Maestro Pro and Maestro Edge Platforms Introduced By Axion BioSytems

Yuvraj_pawp by Yuvraj_pawp
12th September 2017
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Axion BioSystems, the global leader in microelectrode array (MEA) technology, introduces the next generation of MEA platforms, Maestro Pro and Maestro Edge.

Excitable cells play a fundamental role in life, from heart beats to brain function. Maestro MEA systems capture live-cell activity from electroactive cells in real-time, allowing scientists to recreate complex human functions in culture dishes. As a result, scientists can now conduct research that spans from rapid stem cell development to advanced drug screening.
Built on Axion’s latest chip technology, BioCore v4, the next generation Maestro MEA systems make it even easier to perform measurements from excitable cells in your own lab. With “one button setup,” the cell environment automatically adjusts on plate docking, and plate usage is automatically logged for convenient experiment tracking. Both Maestro Pro and Edge run Axion’s most advanced data acquisition and analysis software, AxIS Navigator.

“The explosion of research related to stem cell models has driven the rapid adoption of Maestro MEA systems,” stated Jim Ross, Axion CTO. “Sophisticated data does not have to be tedious and complicated. Maestro Pro and Edge have made the study of excitable cells accessible to all biologists, setting a new standard for measuring electroactive cell function.”


“Our team has been actively using Axion’s Maestro since 2013 to explore the neuronal networks associated with epilepsy with outstanding results,” said Mike Boland, Assistant Professor at Columbia University’s Institute for Genomic Medicine. “I am excited to see the introduction of Axion’s new generation of Maestros. With universities and companies rapidly integrating human iPSC differentiation technology into their labs, there is a growing need for a simple, reliable, and cost-effective tool to track and analyze complex cell models. “


“The Maestro MEA system is the world’s leading MEA platform, and has been our flagship product for the last four years,” stated Tom O’Brien, Axion BioSystems President, and CEO. “Today, Axion’s innovation moves the field forward again. The Maestro Pro is the world’s most advanced MEA platform for the highest throughput applications. The Maestro Edge now allows researchers and clinicians to access Maestro-quality data but at a price that addresses the budget constraints of academic labs.”


The Maestro Pro’s cutting-edge platform has an integrated touch screen for tracking experimental progress, and is capable of recording from 768 electrodes simultaneously. Its companion system, Maestro Edge, is an affordable extension to the Maestro product family, featuring 384-recording electrodes. This new, lower cost instrument will open up Axion’s MEA technology to many more labs. Any scientist can now quickly and easily measure electrical network behavior in live cells in multiwell plates. Now there is nothing to stop you from exploring life’s circuitry.

Previous Post

Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management

Next Post

Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post

Dr Reddy's Labs subsidiary Aurigene and Curis to initiate phase 2 trial of PDL1-VISTA inhibitor 'CA-170' in India

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In